In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype-Reference-Cited by-同舟云学术

In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype

Published:2004-01-08 Issue:3 Volume:18 Page:521-529
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ramakers-van Woerden N L,Beverloo H B,Veerman A J P,Camitta B M,Loonen A H,van Wering E R,Slater R M,Harbott J,den Boer M L,Ludwig W D,Haas O A,Janka-Schaub G E,Pieters R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2403253.pdf

Reference41 articles.

1. Biondi A, Cimino G, Pieters R, Pui CH . Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24–33.

2. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909–1915.

3. Rubnitz JE, Behm FG, Downing JR . 11q23 rearrangements in acute leukemia. Leukemia 1996; 10: 74–82.

4. Heerema NA, Sather HN, Ge J, Arthur DC, Hilden JM, Trigg ME et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) – a report of the Children's Cancer Group. Leukemia 1999; 13: 679–686.

5. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445–455.

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia;Journal of Pediatric Hematology/Oncology;2023-07-03

2. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia;Nature Communications;2023-02-13

3. Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells;BIO-PROTOCOL;2023

4. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response;Nature Medicine;2023-01

5. Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia;Nature Medicine;2022-03-14